Search - tctmd.com

Displaying 961 - 980 of 1456

Sort: Relevancy | Date

Presentation ECHO 2017

Interventional Echocardiography II: PVL and LAA Closure

Presenter: Omar K. Khalique

April 02, 2017

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

L.A. McKeown

March 21, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

Presentation SIF 2017

LAA Closure: First or Second Line Therapy.

Presenter: Brij Maini

March 09, 2017

Presentation SIF 2017

LAA Closure with the WATCHMAN Device: A Perfect Case

Presenter: Ramon Quesada,

March 09, 2017

Presentation SIF 2017

Cardiac CTA for LAA Occlusion Planning and Follow Up

Presenter: Michael J. Rinaldi

March 08, 2017

News Opinion Conversations in Cardiology

Conversations in Cardiology: For Fellows, How Much Structural Heart Disease Training Is Enough?

February 27, 2017

Presentation JIM 2017

Clinical Experience With LAmbre LAA CLOSURE System

Presenter: Horst Sievert

February 09, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2017

Caitlin E. Cox

February 01, 2017

News Daily News

LAA Thrombus Explored as Potential Cause of Stroke After TAVR

Todd Neale

January 16, 2017

News Daily News

More A-fib, No Drop in Stroke or Death With Surgical Left Atrial Appendage Exclusion

Todd Neale

December 05, 2016

News Conference News

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Todd Neale

November 04, 2016

News Industry News

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

November 02, 2016

Presentation TCT 2016

Management of Residual Leaks After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Follow-up Evaluation After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw, Bushra S Rana

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Advertisement

Interventional Echocardiography II: PVL and LAA Closure

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

Live From Washington: ACC 2017, Day Three

LAA Closure: First or Second Line Therapy.

LAA Closure with the WATCHMAN Device: A Perfect Case

Cardiac CTA for LAA Occlusion Planning and Follow Up

Conversations in Cardiology: For Fellows, How Much Structural Heart Disease Training Is Enough?

Clinical Experience With LAmbre LAA CLOSURE System

TCTMD’s Top 10 Most Popular Stories for January 2017

LAA Thrombus Explored as Potential Cause of Stroke After TAVR

More A-fib, No Drop in Stroke or Death With Surgical Left Atrial Appendage Exclusion

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

Management of Residual Leaks After LAA Closure

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Follow-up Evaluation After LAA Closure

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content